ST天圣(002872) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was approximately ¥489.90 million, down 3.43% year-on-year[7] - Net profit attributable to shareholders was approximately ¥35.43 million, a decline of 38.47% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was approximately ¥31.15 million, down 36.29% year-on-year[7] - Basic earnings per share were ¥0.1114, a decrease of 38.49% compared to the same period last year[7] - Total operating revenue for Q3 2018 was CNY 489.90 million, a decrease of 3.4% from CNY 507.27 million in Q3 2017[37] - Net profit for Q3 2018 was CNY 37.34 million, down 37.2% from CNY 59.53 million in Q3 2017[39] - The company reported a total comprehensive income of CNY 79,754,405.57, down from CNY 93,762,931.57 in the previous year, representing a decline of 15%[51] - Basic and diluted earnings per share were both CNY 0.2522, down from CNY 0.2946 in the same quarter last year, a decrease of 14.4%[51] Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.83 billion, a decrease of 3.51% compared to the previous year[7] - The total current assets decreased from CNY 2,138,733,093.65 at the beginning of the period to CNY 1,788,905,685.84 by the end of the period, representing a decline of approximately 16.3%[30] - Total liabilities decreased from CNY 1,824,537,281.19 to CNY 1,548,786,460.59, a decline of approximately 15.1%[32] - The company's equity increased from CNY 3,186,226,355.30 to CNY 3,286,167,859.10, representing a growth of about 3.1%[32] - Total assets increased to CNY 3.64 billion, up from CNY 3.48 billion year-over-year[36] - Total liabilities rose to CNY 867.96 million, compared to CNY 737.08 million in the previous year[36] Cash Flow - The net cash flow from operating activities was approximately ¥52.14 million, an increase of 139.78% compared to the previous year[7] - Operating cash flow for the period was CNY 90,847,545.43, a significant improvement from a negative cash flow of CNY -246,366,424.15 in the previous year[54] - The company reported a total cash inflow from operating activities of ¥757,732,841.00, compared to ¥1,040,516,177.93 in the previous year[58] - Cash inflow from financing activities totaled ¥269,800,000.00, with cash outflow amounting to ¥313,862,507.75, leading to a net cash flow of -¥44,062,507.75[59] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,449[11] - The largest shareholder, Liu Qun, holds 32.38% of the shares, amounting to 102,961,732 shares[11] - The first major shareholder, Liu Qun, is related to the ninth major shareholder, Liu Wei, indicating a familial connection among key stakeholders[18] Regulatory and Compliance - The company received drug registration approval for injectable Cefoperazone (0.5g, 1.0g, and 2.0g) from the National Medical Products Administration[16] - A subsidiary, Chongqing Guozhong Traditional Chinese Medicine Co., Ltd., was ordered to recall certain traditional Chinese medicine products due to safety concerns[16] - The company reported no violations regarding external guarantees during the reporting period[23] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[24] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[13] Research and Development - Research and development expenses rose to CNY 10.37 million, an increase of 39.5% from CNY 7.45 million in Q3 2017[37] - Research and development expenses increased to CNY 23,918,388.54, up from CNY 18,065,954.45, reflecting a growth of 32.5% year-over-year[50] Government Support - The company received government subsidies amounting to approximately ¥24.08 million during the reporting period[9] Investment Activities - The company reported an investment income of CNY 1,219,800.00, compared to CNY 120,000.00 in the previous year, showing a substantial increase[46] - The company received ¥200,000,000.00 from investment recoveries during the quarter[58]